Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 3:26 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1273–1296 of 1,552 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: IBD Clear all
Completed Not applicable Interventional

CBT-I for Sleep, Pain, and Inflammation in Crohn's Disease

NCT05034159
View directory record Official record
Conditions
Crohn Disease, Insomnia, Sleep Disturbance, Pain, Inflammation
Interventions
Cognitive Behavioral Therapy for Insomnia
Behavioral
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated May 18, 2023 · Synced Oct 28, 2026, 3:26 AM EDT
Not listed No phase listed Observational

Infliximab Proactive Drug Monitoring in the Pediatric IBD Population

NCT04921670
View directory record Official record
Conditions
Inflammatory Bone Disease
Interventions
Infliximab Assay
Diagnostic Test
Lead sponsor
Cares, Kristen, M.D.
Other
Eligibility
5 Years to 21 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 28, 2026, 3:26 AM EDT
Recruiting Not applicable Interventional

Testing the Impact of Measurement-Based Care on Quality of Life and Disease Management Among Veterans With Inflammatory Bowel Disease

NCT07210580
View directory record Official record
Conditions
Inflammatory Bowel Disease
Interventions
MBC-IBD Intervention, Enhanced Treatment as Usual (E-TAU)
Behavioral · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
4
States / cities
Decatur, Georgia • Ann Arbor, Michigan • Portland, Oregon + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Oct 28, 2026, 3:26 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Asacol 4.8 g/Day Versus Asacol 2.4 g/Day (ASCEND I)

NCT00577473
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
mesalamine
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
18 Years to 65 Years
Enrollment
301 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
44
States / cities
Birmingham, Alabama • Anaheim, California • Sacramento, California + 41 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2011 · Synced Oct 28, 2026, 3:26 AM EDT
Terminated No phase listed Observational

UCB Cimzia Pregnancy Follow-up Study

NCT02775656
View directory record Official record
Conditions
Rheumatoid Arthritis (RA), Crohn's Disease (CD), Psoriatic Arthritis (PsA), Axial Spondyloarthritis and Ankylosing Spondylitis
Interventions
Not listed
Lead sponsor
UCB BIOSCIENCES, Inc.
Industry
Eligibility
18 Years to 64 Years · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Wilmington, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 22, 2021 · Synced Oct 28, 2026, 3:26 AM EDT
Completed Phase 3 Interventional Results available

12-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)

NCT02107196
View directory record Official record
Conditions
Irritable Bowel Syndrome With Diarrhea
Interventions
Ibodutant 10 mg, Placebo
Drug
Lead sponsor
Menarini Group
Industry
Eligibility
18 Years and older · Female only
Enrollment
535 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
65
States / cities
Huntsville, Alabama • Sherwood, Arizona • Little Rock, Arkansas + 56 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2017 · Synced Oct 28, 2026, 3:26 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Malnutrition Associated With Complications After Ileostomy Reversal

NCT03909542
View directory record Official record
Conditions
Inflammatory Bowel Diseases, Ileostomy
Interventions
Not listed
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
Not listed
Enrollment
359 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 10, 2019 · Synced Oct 28, 2026, 3:26 AM EDT
Recruiting Phase 2 Interventional

A Study to Test Whether BI 3032950 Helps People With Ulcerative Colitis

NCT06636656
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
BI 3032950 intravenous (Part A), BI 3032950 subcutaneous (Part B)
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 80 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
14
States / cities
Scottsdale, Arizona • Colorado Springs, Colorado • Kissimmee, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 28, 2026, 3:26 AM EDT
Terminated Phase 3 Interventional Results available

A Study of Guselkumab for the Treatment of Participants With Crohn's Disease After Surgical Resection

NCT05784129
View directory record Official record
Conditions
Crohn's Disease
Interventions
Guselkumab, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
9
States / cities
San Diego, California • Naples, Florida • Macon, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 28, 2026, 3:26 AM EDT
Active, not recruiting Not applicable Interventional Results available

A Study of Endoscopic Sleeve Gastroplasty for Obesity in Ulcerative Colitis

NCT05739162
View directory record Official record
Conditions
Obesity, Ulcerative Colitis
Interventions
Apollo Endoscopic Suture System, Lifestyle Intervention
Device · Behavioral
Lead sponsor
Mayo Clinic
Other
Eligibility
22 Years to 69 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 28, 2026, 3:26 AM EDT
Completed Not applicable Interventional

Effect of HMOs as Nutritional Support for Normal Bowel Movements in IBS Patients

NCT03550742
View directory record Official record
Conditions
Irritable Bowel Syndrome (IBS)
Interventions
Fuco-N-Tetraose
Other
Lead sponsor
Glycom, Inc.
Industry
Eligibility
18 Years and older
Enrollment
317 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 25, 2019 · Synced Oct 28, 2026, 3:26 AM EDT
Completed Phase 2 Interventional Results available

GSK2982772 Study in Subjects With Ulcerative Colitis

NCT02903966
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
GSK2982772, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
6
States / cities
Moreno Valley, California • San Diego, California • Marrero, Louisiana + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2020 · Synced Oct 28, 2026, 3:26 AM EDT
Terminated Phase 2 Interventional

A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Crohn's Disease.

NCT06637631
View directory record Official record
Conditions
Crohn's Disease
Interventions
SAR441566, SAR441566 matching Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 75 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
19
States / cities
Sun City, Arizona • Bristol, Connecticut • Clermont, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 28, 2026, 3:26 AM EDT
Withdrawn Phase 1 Interventional

Stem Cells for the Treatment of Pouchitis

NCT05578508
View directory record Official record
Conditions
Pouchitis, Crohn's Disease, Ulcerative Colitis Chronic, Inflammatory Bowel Diseases, Pouch, Ileal
Interventions
Mesenchymal Stem Cells (MSCs)
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Oct 28, 2026, 3:26 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate Safety and Efficacy of Telotristat Etiprate (LX1606) in Participants With Acute, Mild to Moderate Ulcerative Colitis

NCT01456052
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Telotristat Etiprate, Placebo
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
11
States / cities
Little Rock, Arkansas • Anaheim, California • Santa Monica, California + 8 more
Source: ClinicalTrials.gov public record
Updated May 23, 2019 · Synced Oct 28, 2026, 3:26 AM EDT
Completed Not applicable Interventional Results available

Effect of Lubiprostone on Small Bowel Contractions in Female Patients With Constipation Irritable Bowel Syndrome (C-IBS)

NCT01085643
View directory record Official record
Conditions
Constipation-predominant Irritable Bowel Syndrome
Interventions
Lubiprostone, Placebo
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 12, 2011 · Synced Oct 28, 2026, 3:26 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Assessing Symptom and Mood Dynamics in Pain Using the Smartphone Application SOMA

NCT05754190
View directory record Official record
Conditions
Chronic Pain, Acute Pain, Post Operative Pain, Fibromyalgia, Primary, Fibromyalgia, Secondary, Fibromyalgia, Irritable Bowel Syndrome, Chronic Headache Disorder, Chronic Migraine, Chronic Pelvic Pain Syndrome, Temporomandibular Joint Disorders, Endometriosis-related Pain, Arthritis, Chronic Low-back Pain, Failed Back Surgery Syndrome, Post Herpetic Neuralgia, Neuropathic Pain, Painful Diabetic Neuropathy, Painful Bladder Syndrome, Trauma-related Wound, Trauma, Multiple, Chronic Pain Syndrome, Chronic Shoulder Pain
Interventions
SOMA pain manager smartphone application
Device
Lead sponsor
Brown University
Other
Eligibility
18 Years and older
Enrollment
800 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Sep 19, 2025 · Synced Oct 28, 2026, 3:26 AM EDT
Completed Phase 2 Interventional

A Study of BMS-562086 in Patients With Irritable Bowel Syndrome

NCT00399438
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Placebo, BMS-562086
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 26, 2008 · Synced Oct 28, 2026, 3:26 AM EDT
Terminated Phase 2Phase 3 Interventional

Study of Visilizumab Versus Placebo in Subjects With Intravenous Steroid-refractory Ulcerative Colitis Previously Responsive in a Visilizumab Study

NCT00279435
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
visilizumab
Drug
Lead sponsor
Facet Biotech
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
9
States / cities
Atlanta, Georgia • Louisville, Kentucky • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2012 · Synced Oct 28, 2026, 3:26 AM EDT
Recruiting Not applicable Interventional

A Pilot Study to Assess the Safety, Tolerability, and Efficacy of Virtual Reality for the Treatment of Abdominal Pain in Quiescent Crohn's Disease

NCT06647615
View directory record Official record
Conditions
Crohn's Disease, Abdominal Pain (AP)
Interventions
VR headset
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Oct 28, 2026, 3:26 AM EDT
Completed Not applicable Interventional

Smartphone Training for Attention Regulation for IBS

NCT05083091
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Mindfulness and Attention Training, Mindfulness training, Coping Condition
Behavioral
Lead sponsor
Carnegie Mellon University
Other
Eligibility
18 Years and older
Enrollment
359 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 26, 2025 · Synced Oct 28, 2026, 3:26 AM EDT
Completed Not applicable Interventional Results available

Stress in Inflammatory Bowel Disease

NCT05202418
View directory record Official record
Conditions
Inflammatory Bowel Diseases, Psychological
Interventions
Biofeedback Enhanced Treatment
Behavioral
Lead sponsor
Emory University
Other
Eligibility
13 Years to 18 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 22, 2025 · Synced Oct 28, 2026, 3:26 AM EDT
Withdrawn Phase 2 Interventional

Autologous Transplant Targeted Against Crohn's

NCT04154735
View directory record Official record
Conditions
Crohn's Disease
Interventions
Fludarabine, Cyclophosphamide, Mesna, Alemtuzumab, G-CSF, Rifaximin, Tacrolimus
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 49 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 8, 2019 · Synced Oct 28, 2026, 3:26 AM EDT
Withdrawn No phase listed Observational

Mucosal Innate Immune Activation in Chronic Intestinal Disorders

NCT03529318
View directory record Official record
Conditions
Irritable Bowel Syndrome, Inflammatory Bowel Diseases
Interventions
Biopsies from endoscopy
Procedure
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 99 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Oct 22, 2019 · Synced Oct 28, 2026, 3:26 AM EDT